Ig-E Mediated Food Allergy

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

RAPT Therapeutics
RAPT TherapeuticsSOUTH SAN FRANCISCO, CA
1 program
1
RPT904Phase 21 trial
Active Trials
NCT07220811Recruiting100Est. Jan 2028

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
RAPT TherapeuticsRPT904

Clinical Trials (1)

Total enrollment: 100 patients across 1 trials

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Start: Oct 2025Est. completion: Jan 2028100 patients
Phase 2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 100 patients
1 companies competing in this space